T stage | Interval of the last follow-up US (month: mean ± SD, range) | Tumor recurrence/persistence (%) |
T1a (n = 278) | 53.7 ± 22.9 (5-90) | 6 (2.2) |
T1b (n = 167) | 55.4 ± 23.1 (8-91) | 16 (9.6) |
T2 (n = 71) | 57.0 ± 20.2 (10-84) | 8 (11.3) |
T3a (n = 7) | 64.6 ± 23.5 (14-84) | 1 (14.3) |
T3b (n = 2) | 54 ± 2.8 (52-56) | 0 |
T4a (n = 0) | NA | NA |
T4b (n = 0) | NA | NA |
N stage | Interval of the last follow-up US (month: mean ± SD, range) | Tumor recurrence/persistence (%) |
N0 (n = 253) | 53.1 ± 22.9 (5-90) | 2.0 (5) |
N1a (n = 226) | 55.1 ± 22.7 (6-91) | 8.0 (18) |
N1b (n = 46) | 60.9 ± 21.9 (0-89) | 17.4 (8) |